{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:05:19Z","timestamp":1789679119316,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Doravirine (DOR) is a newly approved antiretroviral belonging to the class of non-nucleoside reverse transcriptase inhibitors (NNRTI), well tolerated and leading to an improved lipid profile in antiretroviral experienced people living with HIV (PLWH). We aimed at evaluating if the lipid-lowering effect is linked to the drug class, using real-life data from the SCOLTA cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We compared the lipid profile modifications in experienced PLWH switching to a DOR-based regimen from rilpivirine or another NNRTI-based regimen or from an integrase strand transferase (INSTI)-based regimen. T0 and T1 were defined as the baseline and 6-month follow-up respectively. Data were collected at baseline and prospectively every six months and changes from baseline were compared using a multivariable linear model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 107 PLWH, enrolled in the SCOLTA DOR cohort, with undetectable HIV-RNA at baseline, 32.7% switched from RPV-based regimens (DOR1), 29.9% from other NNRTI-including regimens (DOR2) and 37.4% switched from INSTI-including regimens (DOR3). At T1, TC significantly decreased in DOR2 (-15\u00a0mg\/dL) and DOR3 (-23\u00a0mg\/dL), and significantly more in DOR3 than in DOR1 (-6\u00a0mg\/dL) (p\u2009=\u20090.016). HDL-C declined in DOR2 (-2\u00a0mg\/dL) whereas it increased in DOR1 (+\u20093\u00a0mg\/dL) (p\u2009=\u20090.042) and remained stable in DOR3. LDL-C significantly decreased from baseline in DOR2 (-12\u00a0mg\/dL) and DOR3 (-22\u00a0mg\/dL) and was different between DOR1 (-8\u00a0mg\/dL) and DOR3 (p\u2009=\u20090.022). TC\/HDL ratio showed a significant decline in the DOR3 group (-0.45), although similar to DOR1 (-0.23, p\u2009=\u20090.315) and DOR2 (-0.19, p\u2009=\u20090.254). Triglycerides did not noticeably change. ALT significantly decreased in PLWH with a baseline level\u2009&gt;\u200940 UI\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PLWH on doravirine treatment showed different trends in blood lipids according to their previous regimen. In PLWH switching from RPV, minimal modifications were seen, whereas in those switching from other NNRTIs and from INSTI-including regimens, we observed an overall improvement in lipid profile, seemingly independent of the \u201cstatin effect\u201d of TDF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-023-08191-2","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T04:18:12Z","timestamp":1681445892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens"],"prefix":"10.1186","volume":"23","author":[{"given":"Paolo","family":"Maggi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Delfina","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Cicalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Francesco","family":"Pellican\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto Maurizio","family":"Celesia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Sarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Orofino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Squillace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Bargiacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Molteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addolorata","family":"Masiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Saracino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Menzaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Falasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Taramasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"8191_CR1","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","volume":"5","author":"JM Molina","year":"2018","unstructured":"Molina JM, Squires K, Sax PE, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e211\u201320. https:\/\/doi.org\/10.1016\/S2352-3018(18)30021-3.","journal-title":"Lancet HIV"},{"key":"8191_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/cid\/ciy540","volume":"68","author":"C Orkin","year":"2019","unstructured":"Orkin C, Squires KE, Molina JM, et al. Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate is non-inferior to Efavirenz\/Emtricitabine\/Tenofovir Disoproxil Fumarate in treatment-naive adults with human immunodeficiency Virus-1 infection: Week 48 results of the DRIVE-AHEAD trial. Clin Infect Dis. 2019;68:535\u201344. https:\/\/doi.org\/10.1093\/cid\/ciy540.","journal-title":"Clin Infect Dis"},{"key":"8191_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/hiv.13366","volume":"24","author":"JM Garcia","year":"2023","unstructured":"Garcia JM, Dong Y, Richardson P, et al. Effect of HIV and antiretroviral therapy use on body weight changes in a cohort of U.S. veterans living with and without HIV. HIV Med. 2023;24:180\u201390. https:\/\/doi.org\/10.1111\/hiv.13366.","journal-title":"HIV Med"},{"key":"8191_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12981-022-00457-0","volume":"19","author":"A Cozzi-Lepri","year":"2022","unstructured":"Cozzi-Lepri A, Petres L, Pelchen-Matthews, et al. Observational cohort study of rilpivirine (RPV) utilization in Europe. AIDS Res Ther. 2022;19:38. https:\/\/doi.org\/10.1186\/s12981-022-00457-0.","journal-title":"AIDS Res Ther"},{"key":"8191_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/QAD.0000000000002725","volume":"35","author":"C Orkin","year":"2021","unstructured":"Orkin C, Elion R, Thompson M, et al. Changes in weight and BMI with first line doravirine-based therapy. AIDS. 2021;35:91\u20139. https:\/\/doi.org\/10.1097\/QAD.0000000000002725.","journal-title":"AIDS"},{"key":"8191_CR6","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3390\/cells10071687","volume":"10","author":"AM Benedicto","year":"2021","unstructured":"Benedicto AM, Fuster-Mart\u00ednez I, Tosca J, Esplugues JV, Blas-Garc\u00eda A, Apostolova N. NNRTI and liver damage: evidence of their Association and the Mechanisms involved. Cells. 2021;10:1687. https:\/\/doi.org\/10.3390\/cells10071687.","journal-title":"Cells"},{"key":"8191_CR7","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3390\/cells10051263","volume":"10","author":"AO Otto","year":"2021","unstructured":"Otto AO, Rivera CG, Zeuli JD, Temesgen Z. Hepatotoxicity of contemporary antiretroviral drugs: a review and evaluation of published Clinical Data. Cells. 2021;10:1263. https:\/\/doi.org\/10.3390\/cells10051263.","journal-title":"Cells"},{"key":"8191_CR8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2147\/IDR.S152090","volume":"11","author":"P Bagella","year":"2018","unstructured":"Bagella P, De Socio GVL, Ricci E, et al. Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA project. Inf Drug Resist. 2018;11:615\u201323. https:\/\/doi.org\/10.2147\/IDR.S152090.","journal-title":"Inf Drug Resist"},{"key":"8191_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/hiv.12274","volume":"17","author":"J Casado","year":"2016","unstructured":"Casado J, Mena A, Ba\u00f1\u00f3n S, et al. Liver toxicity and risk of discontinuation in HIV\/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis. HIV Med. 2016;17:62\u20137. https:\/\/doi.org\/10.1111\/hiv.12274.","journal-title":"HIV Med"},{"key":"8191_CR10","doi-asserted-by":"publisher","first-page":"e0155842","DOI":"10.1371\/journal.pone.0155842","volume":"11","author":"K Neukam","year":"2016","unstructured":"Neukam K, Espinosa M, Collado A, et al. Hepatic safety of Rilpivirine\/Emtricitabine\/Tenofovir Disoproxil Fumarate fixed-dose single-tablet regimen in HIV-Infected patients with active Hepatitis C virus infection: the hEPAtic study. PLoS ONE. 2016;11:e0155842. https:\/\/doi.org\/10.1371\/journal.pone.0155842.","journal-title":"PLoS ONE"},{"key":"8191_CR11","unstructured":"LiverTox. Clinical and research information on drug-induced liver injury. Doravirine. Last update April 2019. Last accessed on February 22, 2023 at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548267\/?report=reader"},{"key":"8191_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/01.qai.0000164248.56722.3c","volume":"39","author":"P Bonfanti","year":"2005","unstructured":"Bonfanti P, Martinelli C, Ricci E, CISAI Group (Italian Coordinators for the Study of Allergies HIV Infection), et al. An italian approach to post marketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir\/ritonavir. J Acquir Immune Defic Syndr. 2005;39:317\u201320. https:\/\/doi.org\/10.1097\/01.qai.0000164248.56722.3c.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"8191_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1097\/QAI.0000000000002642","volume":"87","author":"P Kumar","year":"2021","unstructured":"Kumar P, Johnson M, Molina J-M, Rizzardini G, Cahn P, Bickel M, et al. Brief report: switching to DOR\/3TC\/TDF maintains HIV-1 virologic suppression through Week 144 in the DRIVE-SHIFT trial. JAIDS J Acquir Immune Defic Syndr. 2021;87:801\u20135. https:\/\/doi.org\/10.1097\/QAI.0000000000002642.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"8191_CR14","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1097\/QAD.0b013e32833ad8b4","volume":"24","author":"M Tungsiripat","year":"2010","unstructured":"Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24:1781\u20134. https:\/\/doi.org\/10.1097\/QAD.0b013e32833ad8b4.","journal-title":"AIDS"},{"key":"8191_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3851\/IMP1518","volume":"15","author":"PA Randell","year":"2010","unstructured":"Randell PA, Jackson AG, Zhong L, et al. The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers. Antivir Ther. 2010;15:227\u201333. https:\/\/doi.org\/10.3851\/IMP1518.","journal-title":"Antivir Ther"},{"key":"8191_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/cid\/civ296","volume":"61","author":"JR Santos","year":"2015","unstructured":"Santos JR, Saumoy M, Curran A, et al. The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind placebo-controlled trial. Clin Infect Dis. 2015;61:403\u20138. https:\/\/doi.org\/10.1093\/cid\/civ296.","journal-title":"Clin Infect Dis"},{"key":"8191_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jama.292.2.191","volume":"292","author":"JE Gallant","year":"2004","unstructured":"Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir df vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191\u2013201. https:\/\/doi.org\/10.1001\/jama.292.2.191.","journal-title":"JAMA"},{"key":"8191_CR18","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3851\/IMP2305","volume":"17","author":"G Behrens","year":"2012","unstructured":"Behrens G, Maserati R, Rieger A, et al. Switching to tenofovir\/emtricitabine from abacavir\/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther. 2012;17:1011\u201320. https:\/\/doi.org\/10.3851\/IMP2305.","journal-title":"Antivir Ther"},{"key":"8191_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/QAD.0b013e328341f925","volume":"25","author":"HM Crane","year":"2011","unstructured":"Crane HM, Grunfeld C, Willig JH, et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS. 2011;25:185\u201395. https:\/\/doi.org\/10.1097\/QAD.0b013e328341f925.","journal-title":"AIDS"},{"key":"8191_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/cid\/ciy083","volume":"67","author":"DV Glidden","year":"2018","unstructured":"Glidden DV, Mulligan K, McMahan V, et al. Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine. Clin Infect Dis. 2018;67:411\u20139. https:\/\/doi.org\/10.1093\/cid\/ciy083.","journal-title":"Clin Infect Dis"},{"key":"8191_CR21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/apt.14218","volume":"46","author":"AA Shaheen","year":"2017","unstructured":"Shaheen AA, AlMattooq M, Yazdanfar S, et al. Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers. Aliment Pharmacol Ther. 2017;46:599\u2013604. https:\/\/doi.org\/10.1111\/apt.14218.","journal-title":"Aliment Pharmacol Ther"},{"key":"8191_CR22","doi-asserted-by":"publisher","first-page":"100873","DOI":"10.1016\/j.aohep.2022.100873","volume":"28","author":"D Contreras","year":"2023","unstructured":"Contreras D, Gonz\u00e1lez-Rocha A, Clark P, Barquera S, Denova-Guti\u00e9rrez E. Diagnostic accuracy of blood biomarkers and non-invasive scores for the diagnosis of NAFLD and NASH: systematic review and meta-analysis. Ann Hepatol. 2023;28:100873. https:\/\/doi.org\/10.1016\/j.aohep.2022.100873.","journal-title":"Ann Hepatol"},{"key":"8191_CR23","unstructured":"Moriles KE, Azer SA. Alanine Amino Transferase. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. 2022 Nov 2. Last accessed on February 22, 2023 at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559278\/"},{"key":"8191_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.19198\/JHA31543","volume":"7","author":"CISAI Group (Gruppo Coordinamento Italiano Studio Allegrie e Infezione da HIV)","year":"2022","unstructured":"CISAI Group (Gruppo Coordinamento Italiano Studio Allegrie e Infezione da HIV). Lipid and transaminase elevation in antiretroviral treatment experienced people living with HIV, initiating a doravirine-based regimen. JHA. 2022;7:72\u20138. https:\/\/doi.org\/10.19198\/JHA31543.","journal-title":"JHA"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08191-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08191-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08191-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T04:21:24Z","timestamp":1681446084000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08191-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8191"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08191-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"assertion":[{"value":"13 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The SCOLTA Project was conducted in accordance with the Declaration of Helsinki. It was approved by Local Ethics committee L. Sacco Hospital, Milano, Italy, on September 18th, 2002, emended on June 13th, 2013 (protocol no. 352\/2013), on December 20th, 2019 (Protocol no. 54085\/2019) and on March 3rd, 2020 (Protocol no. 2020\/EM\/029). All patients included gave their written informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The following authors served as consultant or advisory board and\/or received speaker\u2019s fees and\/or received research grants for their institutions, outside the present work: PM and GFP from Gilead Science, ViiV Healthcare, Janssen and Merck Sharp & Dohme. PB from Gilead Science, ViiV Healthcare, Janssen, Merck Sharp & Dohme and Pfizer. ADB from Gilead Science, ViiV Healthcare and Janssen. RB from Gilead Science, ViiV Healthcare, and Merck Sharp & Dohme. AC from Gilead Science, Janssen, Merck Sharp & Dohme; NS from ViiV Healthcare and Janssen; LT from ViiV Healthcare and Gilead Science; GVDS from ViiV Healthcare. All remaining authors have no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"227"}}